Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
A shareholder of MPLT has filed a Rule 144 notice to sell 12,116 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of 220,685.67. The issuer had 45,373,033 shares outstanding when this notice was prepared.
The shares to be sold were acquired on 01/23/2026 through vesting of restricted stock under a registered plan, treated as payment for services rendered. Over the prior three months, the same seller, Robert Malenka, completed several sales of MPLT common stock, including 21,262 shares on 01/29/2026 for gross proceeds of 394,469.63.
MapLight Therapeutics director Timothy John Garnett reported an open‑market purchase of Voting Common Stock on February 10, 2026. Through the Timothy J Garnett Revocable Trust, he bought 14,124 shares at a weighted average price of $17.89 per share, with individual trades between $17.76 and $17.90. Following this transaction, the trust holds 14,124 shares indirectly for him, and he also holds 49,525 shares directly.
MapLight Therapeutics director Robert C. Malenka sold shares of voting common stock mainly to cover taxes tied to equity awards. On February 10, 2026 he sold 6,622 shares at a weighted average price of $18.12, and on February 11, 2026 he sold 241 shares at $18.00.
According to the footnotes, these sales were made to satisfy tax obligations upon settlement of restricted stock units. After the transactions, he directly owned 351,370 shares of voting common stock and indirectly held 31,672 shares through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power.
The remaining securities are still subject to a lock-up agreement related to MapLight Therapeutics’ initial public offering, under which he agreed, with certain exceptions, not to sell or transfer shares for 180 days following the final prospectus dated October 26, 2025.
Robert Malenka filed a Form 144 notice to sell MPLT common stock. The filing covers a planned sale of 241 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of 4338.00, to be sold on or about 02/11/2026 on NASDAQ.
The 241 shares were acquired on 01/23/2026 as restricted stock vesting under a registered plan, in exchange for services rendered. The notice also lists recent sales of MPLT common stock during the past three months, including 21,262 shares sold on 01/29/2026 for gross proceeds of 394469.63 and 7,039 shares sold on 02/02/2026 for 126835.04.
Robert Malenka has filed a Form 144 notice to sell 6,622 shares of MPLT common stock. The shares were acquired on 01/23/2026 through restricted stock vesting under a registered plan, as payment for services rendered.
The planned sale, with an aggregate market value of $119,962.83, is to be executed through Morgan Stanley Smith Barney LLC on or around 02/10/2026 on the NASDAQ exchange. MPLT had 45,373,033 common shares outstanding at the time listed. Over the prior three months, Malenka reported several MPLT common stock sales totaling tens of thousands of shares and several hundred thousand dollars in gross proceeds.
MapLight Therapeutics executive Jonathan Gillis received new equity awards in the form of stock options and restricted stock units (RSUs). On February 5, 2026, he was granted 24,455 employee stock options to buy voting common stock and 6,020 RSUs of voting common stock.
The RSUs vest over time, with one-quarter vesting on January 1, 2027 and the remainder vesting in equal installments each April 1, July 1, October 1, and January 1 thereafter, subject to continued service. The options vest with one-quarter on February 5, 2027 and the rest in equal monthly installments, also contingent on continued service.
MapLight Therapeutics Chief Financial Officer Vishwas Setia reported new equity awards. On February 5, 2026, he acquired 7,730 shares of voting common stock at $0, described as a restricted stock unit (RSU) award. One quarter of these RSUs will vest on January 1, 2027, with the remainder vesting in equal installments on each April 1, July 1, October 1 and January 1 thereafter, contingent on continued service.
Setia was also granted an employee stock option for 31,395 shares of voting common stock at an exercise price of $15.7 per share, expiring on February 4, 2036. One quarter of the option will vest on February 5, 2027, with the balance vesting monthly in equal installments, also subject to continued service. Following these awards, he directly holds 395,549 shares of voting common stock and 31,395 stock options.
MapLight Therapeutics Chief Scientific Officer receives new equity awards. On February 5, 2026, Lillie James Woodruff was granted 7,730 restricted stock units of voting common stock and an option to purchase 31,395 shares at an exercise price of $15.7 per share.
The RSUs vest 25% on January 1, 2027, with the remainder vesting in equal quarterly installments, subject to continued service. The stock option vests 25% on February 5, 2027, with the balance vesting in equal monthly installments thereafter. Following the RSU grant, Woodruff beneficially owns 298,862 shares of voting common stock and 31,395 stock options, all held directly.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported equity awards of 6,020 restricted stock units and 24,455 employee stock options dated February 5, 2026. The RSUs vest 25% on January 1, 2027, with the remaining 75% vesting in equal quarterly installments, subject to continued service.
The options have a $15.70 exercise price and begin vesting with 25% on February 5, 2027, then monthly vesting for the remaining shares. Following the RSU grant, Kreitzer directly holds 259,928 shares of voting common stock, and 24,455 options after the option grant.
MapLight Therapeutics, Inc. reported that its General Counsel, Kristopher Hanson, received new equity awards on February 5, 2026. He acquired 7,730 shares of voting common stock through a restricted stock unit grant at a stated price of $0, bringing his directly held total to 191,582 shares.
He was also granted an employee stock option for 31,395 shares at an exercise price of $15.7 per share. One quarter of the RSUs vest on January 1, 2027, and the remainder in equal quarterly installments, while one quarter of the option vests on February 5, 2027, with the balance vesting monthly thereafter, all contingent on continued service.